Menu
One of the co-investigators of the Prostate Cancer Recurrence Clinical Trial at Memorial Sloan Kettering Cancer Center (MSKCC) is Jonathan Fainberg, MD, MPH, who specializes in localized prostate cancer, focal therapy, and partial ablation, which are methods of precisely treating intermediate-risk prostate cancer. Fainberg will give you insight into prostate cancer, today’s treatments and what potential he sees with SpectraCure’s method.
Want to learn more about Jonathan S. Fainberg and hear what he thinks is unique about SpectraCure? Then don’t miss watching the entire interview below.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.